AnGes MG Inc. | Balance Sheet

Fiscal year is January-December. All values JPY Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
2,295
6,017
2,075
996
1,148
5,785
Total Accounts Receivable
109
659
262
464
235
331
Inventories
619
357
667
2,122
1,995
1,373
Other Current Assets
282
560
1,239
37
56
53
Total Current Assets
3,305
7,594
4,243
3,619
3,434
7,542
Net Property, Plant & Equipment
23
28
76
76
-
47
Total Investments and Advances
474
480
367
772
522
401
Intangible Assets
70
54
51
55
-
-
Other Assets
32
28
16
17
8
60
Total Assets
3,923
8,199
4,766
4,539
3,964
8,051
Accounts Payable
42
207
247
389
201
Income Tax Payable
32
42
33
81
12
Other Current Liabilities
271
174
202
161
105
Total Current Liabilities
345
423
482
631
318
Provision for Risks & Charges
-
15
22
23
23
Deferred Taxes
-
10
26
16
1
Other Liabilities
15
-
-
-
-
Total Liabilities
380
465
544
670
342
Common Equity (Total)
3,544
7,734
4,221
3,869
3,622
Total Shareholders' Equity
3,544
7,734
4,221
3,869
3,622
Total Equity
3,544
7,734
4,221
3,869
3,622
Liabilities & Shareholders' Equity
3,923
8,199
4,766
4,539
3,964

About AnGes MG

View Profile
Address
Saito Bio-Incubator 1F
Osaka Osaka 567
Japan
Employees -
Website http://www.anges.co.jp
Updated 07/08/2019
AnGes, Inc. engages in the research and development of gene-based medical products. It offers genetic medicines such as hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, and others. It is also involved in the research and development of medical equipment, which improves blood circulation by regenerating blood vessels and NfkB which controls various inflammations.